Patients without history of coronary stenting had higher baseline risk of MACE. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. A total of 4199 patients had no history of coronary stenting at baseline. This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1-3 years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). 14 CPC Clinical Research, University of Colorado School of Medicine, 13199 E Montview Blvd Suite 200, Aurora, CO, USA.13 AstraZeneca, 431 53 Mölndal, Sweden.12 College of Medicine, University of the Philippines/Philippine Heart Center, East, Quezon City, Metro Manila, Philippines.11 Department of Cardiology, Military Hospital, Róbert Károly krt., 1134 Budapest, Hungary.10 Cardiovascular Division, Faculty of Medicine, Pontificia Universidad Católica de Chile, Lira 40, Santiago, Chile.9 Drammen Heart Center, DronninggDrammen, Norway. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |